Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
暂无分享,去创建一个
F. Pattou | A. Duhamel | R. Caiazzo | H. Verkindt | V. Raverdy | E. Leteurtre | M. Romon | S. Dharancy | P. Mathurin | J. Labreuche | A. Louvet | M. Pigeyre | D. Buob | G. Lassailly | Hélène Verkindt
[1] F. Pattou,et al. Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.
[2] M. Scotté,et al. Comparison of the Effectiveness of Four Bariatric Surgery Procedures in Obese Patients with Type 2 Diabetes: A Retrospective Study , 2014, Journal of obesity.
[3] Deepak L. Bhatt,et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.
[4] C. Still,et al. Risk Factors Associated With Mortality After Roux-en-Y Gastric Bypass Surgery , 2014, Annals of surgery.
[5] M. Kroh,et al. Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus , 2013, Annals of surgery.
[6] F. Pattou,et al. Bariatric surgery for curing NASH in the morbidly obese? , 2013, Journal of hepatology.
[7] Joan Tordjman,et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.
[8] N. Chalasani,et al. Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .
[9] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[10] Michael Charlton,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.
[11] Richard A. Flavell,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.
[12] R. Abramof. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes , 2012 .
[13] R. Ness-Abramof. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes , 2012 .
[14] J. Alvarez‐Leite,et al. Food quality, physical activity, and nutritional follow-up as determinant of weight regain after Roux-en-Y gastric bypass. , 2012, Nutrition.
[15] Reneé H Moore,et al. A two-year randomized trial of obesity treatment in primary care practice. , 2011, The New England journal of medicine.
[16] J. Crowley,et al. Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .
[17] W. Bilker,et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.
[18] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[19] T. Barrientos-Gutiérrez,et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. , 2010, The Cochrane database of systematic reviews.
[20] D. Houlihan,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[21] F. Pattou,et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.
[22] B. Neuschwander‐Tetri,et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.
[23] G. Aithal,et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.
[24] Alexander Pertsemlidis,et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.
[25] Claude Bouchard,et al. Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.
[26] L. Sjöström. Surgical intervention as a strategy for treatment of obesity , 2000, Endocrine.
[27] J. Barkin. Gastric Bypass Surgery Improves Metabolic and Hepatic Abnormalities Associated With Nonalcoholic Fatty Liver Disease , 2007 .
[28] F. Pattou,et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. , 2006, Gastroenterology.
[29] S. Harrison,et al. Non-Alcoholic Steatohepatitis: Effect of Roux-en-Y Gastric Bypass Surgery , 2006, The American Journal of Gastroenterology.
[30] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[31] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[32] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[33] Henry Buchwald,et al. Bariatric surgery: a systematic review and meta-analysis. , 2004, JAMA.
[34] J. Dixon,et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss , 2004, Hepatology.
[35] D A Follmann,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .
[36] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[37] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[38] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[39] M. Duerson,et al. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. , 1983, The New England journal of medicine.
[40] F. Eriksson. Biliointestinal bypass. , 1981, International journal of obesity.